Distinct roles of different fragments of PDCD4 in regulating the metastatic behavior of B16 melanoma cells

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1725-1733

  Wang, Di ^a   Guo, Shu ^a   Han, Si Yuan ^a   Xu, Nan ^a   Guo, Jia Yan ^a   Sun, Qing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; CXCR4; Melanoma; Metastasis; PDCD4

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GELATINASE A; MESSENGER RNA; PROGRAMMED CELL DEATH 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER TISSUE; CELL CLONE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA B16; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84875974760     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1841     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Haass NK and Herlyn M: Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10: 153-163, 2005.
3. Haass NK, Smalley KS and Herlyn M: The role of altered cell-cell communication in melanoma progression. J Mol Histol 35: 309-318, 2004. (Pubitemid 40585316)
4. Wang Q, Sun ZX, Allgayer H, et al: Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene 29: 128-138, 2010.
5. Shibahara K, Asano M, Ishida Y, et al: Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 166: 297-301, 1995.
6. Jansen AP, Camalier CE and Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 65: 6034-6041, 2005. (Pubitemid 40994387)
7. Soejima H, Miyoshi O, Yoshinaga H, et al: Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet 87: 113-114, 1999. (Pubitemid 30021050)
8. Cmarik JL, Min H, Hegamyer G, et al: Differentially expressed protein PDCD4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 96: 14037-14042, 1999.
9. Chang JH, Cho YH, Sohn SY, et al: Crystal structure of the eIF4A-PDCD4 complex. Proc Natl Acad Sci USA 106: 3148-3153, 2009.
10. Suzuki C, Garces RG, Edmonds KA, et al: PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc Natl Acad Sci USA 105: 3274-3279, 2008. (Pubitemid 351723543)
11. Yang HS, Cho MH, Zakowicz H, et al: A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol 24: 3894-3906, 2004. (Pubitemid 38496167)
12. Zakowicz H, Yang HS, Stark C, et al: Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA 11: 261-274, 2005. (Pubitemid 40270819)
13. LaRonde-LeBlanc N, Santhanam AN, Baker AR, et al: Structural basis for inhibition of translation by the tumor suppressor Pdcd4. Mol Cell Biol 27: 147-156, 2007. (Pubitemid 46013240)
14. Chen Y, Knosel T, Kristiansen G, et al: Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 200: 640-646, 2003. (Pubitemid 36987314)
15. Zhang H, Ozaki I, Mizuta T, et al: Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25: 6101-6112, 2006. (Pubitemid 44562408)
16. Afonja O, Juste D, Das S, et al: Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 23: 8135-8145, 2004. (Pubitemid 39531854)
17. Mudduluru G, Medved F, Grobholz R, et al: Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 110: 1697-1707, 2007. (Pubitemid 47558956)
18. Motoyama K, Inoue H, Mimori K, et al: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 36: 1089-1095, 2010.
19. Jin H, Kim TH, Hwang SK, et al: Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther 5: 1041-1049, 2006. (Pubitemid 43724605)
20. Jansen AP, Camalier CE, Stark C, et al: Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3: 103-110, 2004. (Pubitemid 39193684)
21. Caporali S, Alvino E, Levati L, et al: Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochem Pharmacol 84: 598-611, 2012.
22. Yang CH, Yue J, Pfeffer SR, et al: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 286: 39172-39178, 2011.
23. Rothhammer T, Hahne JC, Florin A, et al: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 61: 118-128, 2004. (Pubitemid 38121905)
24. Amara A, Gall SL, Schwartz O, et al: HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186: 139-146, 1997. (Pubitemid 27304856)
25. Griffiths-Jones S, Grocock RJ, van Dongen S, et al: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144, 2006.
26. Betel D, Wilson M, Gabow A, et al: The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-D153, 2008. (Pubitemid 351149712)
27. Lankat-Buttgereit B and Goke R: The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell 101: 309-317, 2009.
28. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73: 185-191, 2010.
29. Yang HS, Jansen AP, Nair R, et al: A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation. Oncogene 20: 669-676, 2001. (Pubitemid 32179335)
30. Schmid T, Jansen AP, Baker AR, et al: Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 68: 1254-1260, 2008. (Pubitemid 351346830)
31. Leupold JH, Yang HS, Colburn NH, et al: Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 26: 4550-4562, 2007. (Pubitemid 47039134)
32. Böhm M, Sawicka K, Siebrasse JP, et al: The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene 22: 4905-4910, 2003. (Pubitemid 36981280)
33. Yang HS, Jansen AP, Komar AA, et al: The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37, 2003. (Pubitemid 36008498)
34. Tawbi HA and Kirkwood JM: Management of metastatic melanoma. Semin Oncol 34: 532-545, 2007. (Pubitemid 350236308)
35. Gibbs DF, Warner RL, Weiss SJ, et al: Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol 20: 1136-1144, 1999. (Pubitemid 129503231)
36. Shah PK, Falk E, Badimon JJ, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92: 1565-1569, 1995.
37. Jackson C, Nguyen M, Arkell J, et al: Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis-targetting gelatinase A activation. Inflamm Res 50: 183-186, 2001. (Pubitemid 32382244)
38. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004. (Pubitemid 38586742)
39. Kucia M, Jankowski K, Reca R, et al: CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35: 233-245, 2004. (Pubitemid 40585309)
40. Schimanski CC, Schwald S, Simiantonaki N, et al: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11: 1743-1750, 2005. (Pubitemid 40471835)
41. Harvey JR, Mellor P, Eldaly H, et al: Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res 13: 1562-1570, 2007. (Pubitemid 46450448)
42. Zhou W, Jiang Z, Liu N, et al: Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol 135: 91-102, 2009.
43. Turner RR, Ye X, Bilchik AJ, et al: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244: 113-120, 2006. (Pubitemid 44297455)
44. Scala S, Giuliano P, Ascierto PA, et al: Human melanoma metastases express functional CXCR4. Clin Cancer Res 12: 2427-2433, 2006.